Olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps is associated with clinical-cytological grading severity
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disorder, affecting about 4% of the worldwide population and strongly impacting the quality of life. CRSwNP is still a challenge for ENT specialists in terms of its unknown pathogenesis, difficulty in management and frequent relapse. Olfactory impairment frequently affects CRSwNP patients. We tested the hypothesis that clinicalcytological grading (CCG) could be associated with olfactory dysfunction. The study was cross-sectional, enrolling 62 patients (37 males, 25 females, mean age 49 years, range 18-83) suffering from newly diagnosed CRSwNP. Olfactory dysfunction was very frequent (about 90%) and did not depend on nasal obstruction as assessed by both polyp size and nasal airflow limitation. A CCG > 4 was the best cutoff value to suspect olfactory dysfunction [area under the ROC curve of 0.831 (0.715 to 0.914)]; in addition, the statistical risk of having dysosmia was over 7-fold higher in subjects with CCG > 4 compared with subjects reporting a CCG < 4 (adjOR 7.46). The present study underlines that olfactory dysfunction is common in CRSwNP patients and demonstrates an association between olfactory dysfunction and inflammation, suggesting that CCG could be useful in the work-up of CRSwNP patients and in suspecting olfactory impairment.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterised by an inflammatory process involving the nasal mucosa. CRSwNP affects about 4% of the worldwide population and may strongly impair the quality of life 1. CRSwNP represents an intriguing challenge for ENT specialists in terms of its unknown pathogenesis, difficulty in management and frequent relapse.
CRSwNP may be classified according to: comorbidity 2, endoscopic outcomes 3, X-ray features 4, and cytological pattern 5. In particular, a clinical-cytological grading (CCG) has been proposed to better define the management strategy, individuate a prognostic index of relapse 6 and adopt a personalised medical approach 7.
Olfactory defects are common in the general population with a prevalence ranging between 9.5% and 15.3%, which is higher in elderly subjects and males 8. Olfactory defects may be classified as hyposmia (partial defect of smell) and anosmia (total loss of smell). Rhinosinusitis is a common cause of chronic olfactory impairment in patients with nasal disorders 9. Indeed, patients with CRSwNP frequently suffer from olfactory defects 10. A longitudinal study demonstrated that nasal eosinophilia is a negative predictive factor for olfactory recovery after surgery 11. Moreover, it has been reported that improved olfaction significantly enhanced quality of life score 12.
Olfactory exploration is fundamental in patients with CRSwNP 13. Olfactory assessment is based on history, clinical examination (mainly by fibreoptic endoscopy) and smell testing (e.g. psychophysical test Sniffin’Sticks). The “Sniffin’Sticks” olfactometric test has been validated and used in many studies 14. The “Sniffin’Sticks” is a test of nasal chemosensory performance based on pen-like odour from a dispensing device 15. The test evaluates three olfactory functions: odour threshold, odour discrimination and odour identification 16-18.
On the basis of this background, the present study evaluated which factors, including CCG, are associated with olfactory defects in patients with newly diagnosed CRSwNP.
Materials and methods
Sixty-two patients (37 males, 25 females, mean age 49 years, range 18-83 years) were consecutively visited at the Rhinology Unit of the ENT Clinic of the Bari University (Italy) and were enrolled in this cross-sectional study from June 2017 to June 2018.
The inclusion criteria were: 1) age > 18 years of age; 2) male or female; 3) suffering from newly diagnosed CRSwNP; 4) informed written consent.
The exclusion criteria were: 1) current or past treatment for NP; 2) previous functional endoscopic sinus surgery (FESS); 3) past surgery for NP, CRS and septal deviation; 4) severe anatomic defects; 5) secondary olfactory defects; 6) NP limited to the olfactory fissure; 7) severe anatomic defect of the nasal cavity and/or nasal pyramid; 8) workers at chemical industries or exposed to volatile toxic substances; 9) past head trauma or brain injury, recent severe hyperthermia, or neurodegenerative disorders documented by neurological examination.
The Review Board approved the procedures used in this study.
All patients were evaluated by: clinical history, objective examination, fibreoptic endoscopy, nasal cytology, skin prick test, rhinomanometry, pulmonology visit and olfactometric test.
The outcome of the current study was dysosmia as defined and scored below.
Nasal endoscopy was carried out by a 3.4 mm diameter flexible fibrescope (Vision-Sciences® ENT-2000). Nasal polyp endoscopic 4-grade classification proposed by Meltzer was adopted 3.
Nasal cytology includes: sampling, processing and microscope reading. Sampling requires the collection of cells from the surface of middle portion of the inferior turbinate using a sterile disposable curette. The procedure is performed under anterior rhinoscopy, with an appropriate light source, and is completely painless. The sample obtained is immediately smeared on a glass slide, air-dried and stained with May-Grünwald-Giemsa (MGG) for 30 min. The stained sample was examined by optical microscopy with a 1000x objective with oil immersion. Fifty fields are considered the minimum number to identify a sufficient number of cells. The count of each cell type was expressed by a semi-quantitative grading as previously described 20.
Skin prick test was performed as stated by the European Academy of Allergy and Clinical Immunology 21. The allergen panel consisted of the following: house-dust mites (Dermatophagoidesfarinae and Dermatophagoidespteronyssinus), cats, dogs, grasses mix, Compositae mix, P. judaica, birch, hazel trees, olive trees, cypress, Alternaria tenuis, Cladosporium and Aspergilli mix. The concentration of allergen extracts was 100 immune reactivity/mL (Stallergenes-Greer Italia, Milan, Italy). A histamine solution in distilled water (10 mg/mL) was used as a positive control and the glycerol-buffer diluent of allergen preparations was used as a negative control. Each patient was skin tested on the volar surface of the forearm using 1-mm prick lancets. The skin reaction was recorded after 15 min by evaluating the skin response in comparison with the wheal given by the positive and the negative control. A wheal diameter of at least 3 mm was considered as a positive reaction.
Rhinomanometry measured nasal airflow resistance by active anterior electronic rhinomanometry. Patients wore a tight-fitting facemask and breathed through one nostril with their mouth closed. A sensor, placed in the contralateral nostril, recorded data on pre- and postnasal pressures via airflow and pressure transducers. The instrument (Rhinomanometer Menfis, Amplifon, Italy) was connected to a personal computer. The signals of trans-nasal airflow and pressure were amplified, digitalised and saved for statistical analysis. Nasal resistance was measured in ml/sec as the sum of the recorded airflow through the right and left nostrils at a pressure difference of 150 Pa across the nasal passage. Four or more airflow measurements were performed for each patient, and the mean value was recorded when reproducible values were achieved. Normal values are 0.50 Pa/ml/sec.
Clinical-Cytological Grading has been previously described in detail elsewhere 6 7. Briefly, CCG is a score based on both nasal cytology findings and comorbidities, including asthma, allergy and ASA sensitivity. For each variable, a score value was assigned: neutrophilic infiltrate was scored as 1, mast cell infiltrate was scored 1, eosinophilic infiltrate was scored 2, eosinophilic + mast cell was scored 4; similarly, ASA sensitivity scored 1, asthma 2, allergy 2 and ASA sensitivity + asthma 3. The CCG was composed as the sum of these individual scores. A global score between 1-3 is considered low grade, 4-6 moderate and > 7 severe, as reported in Figure 1 6 7.
Sniffin’ Sticks test was performed in all patients and TDI score was calculated according to a Position Paper on olfactory dysfunction 22. The composite TDI score is the sum of each item, including olfactory functions, such as odour threshold, odour discrimination and odour identification. On the basis of the TDI score, patients can be classified as normoosmic (TDI > 30.5), hypoosmic (TDI < 30.5 and > 16.5) and anosmic (TDI < 16.5). In the current study, patients were divided into 2 groups based on normosmia, such as with TDI > 30.5 (n = 7), or dysosmia, such as with TDI < 30.5 (i.e. hyposmia or anosmia; n = 55).
Demographic and clinical characteristics were described using means with SDs for normally-distributed continuous data (i.e. age or CCG) or as absolute frequency and percentages for categorical data (i.e. male gender).
Any statistically significant difference in the mean values among patients with normal or impaired olfaction (i.e. hyposmia or anosmia) was evaluated by ANOVA followed by Bonferroni post hoc test.
Comparison of frequency distributions was made by chi-square test or Fisher’s exact test in case of expected frequencies < 5.
A receiver operating characteristic (ROC) curve analysis was performed to determine a cut-off point for CCG to identify patients with dysosmia (i.e. patients with anosmia or hyposmia). The area under the curve (AUC) is graded as follows: AUC = 0.5, no discrimination (it corresponds to a level of performance of little more than that of chance); 0.7 < AUC < 0.8, acceptable discrimination; 0.8 < AUC < 0.9, excellent discrimination; AUC > 0.9, outstanding discrimination 21. Sensitivity (i.e. the probability of the test being positive when performed on diseased patients), specificity (i.e. the probability of the test being negative when performed on healthy subjects), positive predictive value (PPV, i.e. the probability of the subject being diseased when the test result is positive, negative predictive value (NPV, i.e. the probability of not being diseased with a negative test result, Likelihood Ratio (LR) + (i.e. the ratio between sensitivity divided by 1 - specificity), LR– (i.e. the ratio between 1 - sensitivity divided by specificity), diagnostic Odds ratio (DOR, i.e. the ratio between LR+ and LR–) were reported.
To evaluate the role of different independent explanatory variables in association with dysosmia, multiple logistic regression analysis was performed. Variables that were considered important for the outcome a priori (i.e. age and gender) or that were statistically significant in univariate analysis (P < 0.05) were entered into the model. The effect is expressed as adjusted odds ratio (adjOR) with 95% confidence intervals (CIs). Statistical significance was tested using the likelihood ratio test.
Correlation between the rhinomanometry and olfactometry was evaluated with Spearman’s rank-order correlation coefficient. We labelled the strength of the association as follows: for absolute values of r, 0 to 0.19 is regarded as very weak, 0.2 to 0.39 as weak, 0.40 to 0.59 as moderate, 0.6 to 0.79 as strong and 0.8 to 1 as very strong correlation 23.
Statistical significance was set at p < 0.05, and all analyses were performed using GraphPad Prism software (GraphPad Software Inc, CA, USA) and Epi-Info statistical software (Centers for Disease Control and Prevention, Atlanta, GA, USA).
In CRSwNP patients, olfactory dysfunction was frequent and present in 55 patients with anosmia or hyposmia of 62 patients.
Table I reports demographic and clinical characteristics of the patients. Male gender, age, nasal polyposis severity grading and comorbidities such as allergy, asthma and/or ASA sensitivity were not different among the two groups of subjects. There was a different cytotype profile in the two subgroups: compared to dysosmic patients, in normosmic subjects neutrophils were the most frequently found cells, whereas in dysosmic patients, eosinophils or eosinophils + mast cells were the most frequently found cells.
Mean CCG was significantly higher in dysosmic patients than in normosmic subjects. A low CCG score was detected in over a half of normosmic subjects, whereas there was a medium or a high CCG score in over a half of dysosmic patients.
Since the CCG score was significantly different between normosmic and dysosmic patients, we calculated the best cut-off point for CCG that was able to discriminate between patients with or without dysosmia (i.e. those with ano- or hyposmia or those with normosmia). For this purpose, a ROC curve analysis was performed (Fig. 1). The optimal cut-off value was > 4. Performance measures for CCG as a test for discriminating between patients with dysomia and with normosmia are reported in Table II. The area under the ROC curve was 0.831 (0.715 to 0.914), corresponding to excellent statistical discrimination. LR+ and LR- were 2.48 and 0.41, respectively, with a significant diagnostic odds ratio of 6.09 (1.07-34.73). This means that the risk of having dysosmia was over 6-fold higher in subjects with CCG > 4 compared with subjects with a CCG < 4.
We also evaluated whether age or gender could have an effect on the association between CCG and dysosmia: a logistic regression model of positive CCG (> 4), male gender and age as predictors of the study outcome demonstrated that positive CCG should be considered an independent prognostic factor of olfactory dysfunction in patients with nasal polyps, giving a more than 7-fold higher risk of having dysosmia in subjects with CCG > 4 compared to subjects with a CCG < 4 (adjOR 7.46) (Table III). Figure 2 reports the distribution of normosmia and dysosmia in patients with a CCG > 4 or a CCG < 4. In the group with positive CCG, the proportion of dysosmic patients was significantly higher as to normosmic subjects (Fisher exact test, p = 0.0387).
No correlation was found between olfactometry and rhinomanometry (r = – 0.1978, p = 0.12) (Fig. 3A). There was a moderate and significant inverse relationship between CCG and olfactometry (r = – 0.42; p < 0.0007), as reported in Figure 3B.
The current study demonstrated that olfactory dysfunction is frequent in CRSwNP patients and that there is an association between olfactory impairment and inflammation. In addition, a CCG score > 4 is significantly associated with dysosmia. Actually, CCG could be useful in clinical practice to phenotype CRSwNP patients, identify the best treatment, and avoid under or overtreatment 7 24. Moreover, olfactory dysfunction in patients with CRSwNP is an intriguing topic that is argument of research and clinical debate 25-27.
On the basis of this background, we explored the potential factors associated with olfactory dysfunction in patients with CRSwNP in real-world experience. Notably, about 90% of our CRSwNP patients had olfactory dysfunction that was not associated with nasal obstruction, as evaluated by endoscopy grading and rhinomanometry. On the contrary, olfactory impairment was associated with inflammation, mainly concerning the eosinophilic and mast cell infiltrate.
From a clinical point of view, the assessment of the CCG could also be useful to suspect olfactory impairment in patients with a score > 4. Obviously, a diagnosis of impaired sense of smell should be based on specific olfactory testing.
However, the current study has some limitations, including the small number of patients (overall there was also a relevant imbalance between subgroups: 55 patients with dysosmia and only 7 with normosmia), the common presence of allergic rhinitis and its cross-sectional design. However, the study design was real-world to mirror daily clinical practice and newly diagnosed CRSwNP was a specific inclusion criterion. Therefore, a limited number of patients can be enrolled over a one year period. In addition, as the study was performed in a real-world setting, the percentage of normosmic patients was very low, as expected. Allergic patients were included as this comorbidity is very common and their exclusion drastically diminished the sample size. regarding the third issue, a follow-up longitudinal study is ongoing to evaluate whether CCG can predict persistent olfactory dysfunction over time after surgical treatment.
Nasal cytology has some limitations, including the limited reproducibility due to several factors, such as the area of the scaping, quantity of recovered cells, variations over time and training of the operator. Consequently, these limitations could influence the current findings and their interpretation.
In conclusion, the present study underlines that olfactory dysfunction is common in CRSwNP patients and demonstrates an association between olfactory dysfunction and inflammation and is consistent with findings obtained in the model of obstructive sleep apnoea 28. Moreover, CCG may be useful in the work-up of CRSwNP patients and a CCG score > 4 could lead the clinician to suspect of olfactory impairment.
Figures and tables
|Variable||Dysosmia(n = 55)||Normosmia(n = 7)||P value|
|Male gender||22 (40.00%)||3 (42.86%)||1.00#|
|Age [years, mean (SD)]||50.25 (14.66)||47.43 (15.20)||0.63|
|Grade 1||15 (27.27%)||2 (28.57%)||0.76#|
|Grade 2||13 (23.64%)||3 (42.86%)|
|Grade 3||20 (36.36%)||2 (28.57%)|
|Grade 4||7 (12.73%)||0|
|Allergy||38 (69.09%)||3 (42.86%)||0.21#|
|Asthma||22 (40.00%)||1 (14.29%)||0.24#|
|ASA sensitivity||7 (12.73%)||0||1.00#|
|Asthma + ASA sensitivity||5 (18.52%)||0||0.36#|
|Nasal neutrophils||4 (7.27%)||5 (71.43%)||0.0004#|
|Nasal eosinophils||50 (90.91%)||1 (14.29%)||< 0.0001#|
|Mast cells||25 (45.45%)||1 (14.29%)||0.22#|
|Neutrophils||4 (7.27%)||5 (71.43%)||< 0.0001#|
|Eosinophils||26 (47.27%)||1 (14.29%)|
|Mast cells||1 (1.82%)||1 (14.29%)|
|Eosinophils + mast cells||24 (43.64%)||0|
|CCG [mean (SD)]||5.84 (2.20)||2.86 (2.48)||0.0015|
|Low (≤ 3)||5 (9.09%)||4 (57.14%)||0.012#|
|Medium (4-6)||26 (47.27%)||2 (28.57%)|
|High (≥ 7)||24 (43.64%)||1 (14.29%)|
|Positive predictive value (PPV)||95.1|
|Negative predictive value (NPV)||23.8|
|Likelihood ratio (LR)+||2.48|
|Likelihood ratio (LR)-||0.41|
|Diagnostic odds ratio (DOR)||6.09|
|Outcome||Explanatory variables||Adjusted odds ratio||95% CI||P value|
|Dysosmia (yes vs. no)||CCG (> 4)||7.46||1.18-47.19||0.0328|
- Fokkens WJ, Lund VJ, Mullol J. EPOS2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012; 50:1-12. DOI
- Bachert C, Zhang N, Holtappels G. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010; 126:962-8. DOI
- Meltzer EO, Hamilos DL, Hadley JA. Rhinosinusitis: developing guidance for clinical trials. Rhinosinusitis initiative. J Allergy Clin Immunol. 2006; 118:S17-61. DOI
- Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997; 117:S35-40.
- Gelardi M, Russo C, Fiorella ML. Inflammatory cell types in nasal polyps. Cytopathology. 2010; 2:201-3. DOI
- Gelardi M, Fiorella R, Fiorella ML. Nasal-sinus polyposis: clinical-cytological grading and prognostic index of relapse. J Biol Regul Homeost Agents. 2009; 23:181-8.
- Gelardi M, Iannuzzi L, De Giosa M. Non-surgical management of chronic rhinosinusitis with 1 nasal polyps based on clinical cytological grading: a precision medicine-based approach. Acta Otorhinolaryngol Ital. 2017; 37:38-45. DOI
- Mullol J, Alobid I, Marino-Sanchez F. Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open. 2012; 2:2001256. DOI
- Croy I, Nordin S, Hummel T.. Olfactory disorders and quality of life - an updated review. Chem Senses. 2014; 39:185-94. DOI
- Damm M, Quante G.. Impact of functional endoscopic sinus surgery on symptoms and quality of life in chronic rhinosinusitis. Laryngoscope. 2002; 112:310-5. DOI
- Delank KW, Stoll W.. Olfactory function after functional endoscopic sinus surgery for chronic sinusitis. Rhinology. 1998; 36:15-9.
- Stevenson RJ. Olfactory perception, cognition, and dysfunction in humans. Wiley Interdiscip Rev Cogn Sci. 2013; 4:273-84. DOI
- Nguyen DT, Rumeau C, Gallet P. Olfactory exploration: state of the art. Eur Ann Otolaryngol Head Neck Dis. 2016; 133:113-8. DOI
- Haxel BR, Boessert P, Weyer-Elberich V. Course of olfaction after sinus surgery for chronic rhinosinusitis. Laryngoscope Investig Otolaryngol. 2017; 2:269-75. DOI
- Wolfensberger M, Schnieper S.. Sniffin’Sticks: a new olfactory test battery. Acta Otolaryngol. 2000; 120:303-6. DOI
- Hummel T, Kobal G, Gudziol H. Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol. 2007; 264:237-43. DOI
- Hummel T, Sekinger B, Wolf S. “Sniffin’ Sticks”: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997; 22:39-52. DOI
- Kobal G, Hummel T, Sekinger B. “Sniffin’ Sticks”: screening of olfactory performance. Rhinology. 1996; 34:222-6.
- Orlandi RR, Smith TL, Marple BF. Update on evidence-based reviews with recommendations in adult chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014; 4:S1-15. DOI
- Gelardi M, Iannuzzi L, Quaranta N. Nasal cytology: practical aspects and clinical relevance. Clin Exp Allergy. 2016; 46:785-92. DOI
- Bousquet J, Heinzerling L, Bachert C. Global Allergy and Asthma European Network. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012; 67:18-24. DOI
- Hummel T, Whitcroft KL, Andrews P. Position paper on olfactory dysfunction. Rhinology. 2017; 54:1-3. DOI
- Hosmer DW, Lemeshow S.. Applied logistic regression. John Wiley & Sons: New York; 2000.
- Swinscow TDV. Statistics at square one. BMJ Publishing Group: Southampton; 1997.
- Ottaviano G, Savietto E, Scarpa B. Influence of number of drugs on olfaction in the elderly. Rhinology. 2018; 56:351-357. DOI
- Hopkins C, Philpott C, Crowe S. Identifying the most important outcomes for systematic reviews of interventions for rhinosinusitis in adults: working with patients, public and practitioners. Rhinology. 2016; 54:20-6. DOI
- Pistochini A, Rossi F, Gallo S. Multiple gene expression profiling suggests epithelial dysfunction in polypoid chronic rhinosinusitis. Acta Otorhinolaryngol Ital. 2019; 39:169-77. DOI
- Magliulo G, De Vincentiis M, Iannella G. Olfactory evaluation in obstructive sleep apnoea patients. Acta Otorhinolaryngol Ital. 2018; 38:338-45. DOI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Società Italiana di Otorinolaringoiatria e Chirurgia Cervico Facciale , 2019
- Abstract viewed - 1357 times
- PDF downloaded - 544 times